Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00435227 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness
A Phase 2 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00435227 is a Phase 2 study that was terminated before completion, run by MedImmune. The registered enrollment target is 12 participants.
The verdict
NCT00435227, a Phase 2 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg intramuscular (IM) dose of motavizumab on viral load and motavizumab levels in the upper respiratory tract of children who present with RSV illness but who do not require hospitalization. Using 1:1 randomization, 30 mg/kg motavizumab or placebo will be administered as soon as possible after a child's diagnosis of RSV and his/her eligibility for the study has been confirmed.
Interventions
- OTHER Placebo
- BIOLOGICAL Motavizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-03-20 |
| Est. Completion | 2008-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00435227
The ClinicalTrials.gov registry entry for NCT00435227 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00435227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00435227 about?
NCT00435227 is a clinical study titled "A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness". This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg intramuscular (IM) dose of motavizumab on viral load and motavizumab levels in the upper respiratory tract of children who present with RSV illness but who do not require ...
What is the current status of trial NCT00435227?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2007-03-20. Estimated completion is 2008-05-31.
What interventions are being tested in trial NCT00435227?
The interventions under investigation include: Placebo (OTHER), Motavizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00435227?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.